Development
Pfizer Inc.
PFE
$23.35
$0.231.00%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2023 | 10/01/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 7.69% | 3.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.69% | 3.91% | |||
| Cost of Revenue | 296.79% | 12.72% | |||
| Gross Profit | -88.57% | 1.28% | |||
| SG&A Expenses | 32.20% | -6.60% | |||
| Depreciation & Amortization | 7.46% | -0.42% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 107.91% | 1.99% | |||
| Operating Income | -341.03% | 11.18% | |||
| Income Before Tax | -23.18% | -247.73% | |||
| Income Tax Expenses | 17.53% | -1,257.75% | |||
| Earnings from Continuing Operations | -39.61% | -202.05% | |||
| Earnings from Discontinued Operations | -316.67% | 700.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | 45.45% | |||
| Net Income | -41.44% | -202.36% | |||
| EBIT | -341.03% | 11.18% | |||
| EBITDA | -220.96% | 6.72% | |||
| EPS Basic | -41.41% | -202.35% | |||
| Normalized Basic EPS | -306.81% | 3.30% | |||
| EPS Diluted | -42.66% | -203.00% | |||
| Normalized Diluted EPS | -306.81% | 4.53% | |||
| Average Basic Shares Outstanding | 0.02% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.02% | -1.17% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | -- | -- | |||